ReviewBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2021
The mechanisms and clinical application of Traditional Chinese Medicine Lianhua-Qingwen capsule.
Review in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 6 syntheses or guidelines pooled it, 78 citations in OpenAlex.
- Traditional Chinese Medicine for preventing influenza: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Efficacy and Safety of Traditional Chinese Medicine in Treating Chronic Obstructive Pulmonary Disease with Osteoporosis: A Systematic Review and Meta-Analysis.International journal of chronic obstructive pulmonary disease · 2026Pooled it
- Antidepressant activity of flavones from traditional Chinese medicine: a meta-analysis.Pharmaceutical biology · 2025Pooled it
- Bibliometric analysis of traditional Chinese medicine for viral infections through immune modulation (2015-2025).Frontiers in immunology · 2025Pooled it
- Efficacy and safety of traditional Chinese medicine in the treatment of chronic pulmonary diseases: a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Efficacy and safety of Lianhua Qingwen granule combined with azithromycin forFrontiers in pharmacology · 2024Pooled it
- Comparative clinical trial of Langenlianqiao oral liquid and Lianhuaqingwen capsule in the treatment of mild cases of coronavirus disease 2019 (COVID-19).Journal of health, population, and nutrition · 2024Trial
- Efficacy and safety of Chinese herbal medicine to prevent and treat COVID-19 household close contacts in Hong Kong: an open-label, randomized controlled trial.Frontiers in immunology · 2024Trial
- Recent advances in proteomic strategies for target identification of traditional Chinese medicine.Journal of pharmaceutical analysis · 2026Review
- Therapeutic Applications of Natural Products in Biomedicine and Pharmacotherapy.Life (Basel, Switzerland) · 2026Review
- Modulation of gut microbiota and metabolic profiles by Astragaloside IV in a chronic enteritis model.Frontiers in cellular and infection microbiology · 2026Article
- Influenza virus research in an era of emerging respiratory threats: host-virus interactions, surveillance technologies, antiviral management and resistance, and vaccine preparedness.Frontiers in microbiology · 2026Review
- Feasibility of the inhibitor development for SARS-CoV-2: a systematic approach for drug design.Journal of molecular modeling · 2025Article
- Article
- Chinese Medicine Strategies for Influenza A: Research Progress and Prospects.Chinese journal of integrative medicine · 2025Review
- Quantifying compatibility mechanisms in traditional Chinese medicine with interpretable graph neural networks.Journal of pharmaceutical analysis · 2025Article
- Integrating ICP-MS and Chemometrics for Profiling Inorganic Elements in Lianhua Qingwen Capsules and Evaluating Health Risk.Biological trace element research · 2025Article
- Effectiveness of Lianhua Qingwen Granule and Jingyin Gubiao Prescription in Omicron BA.2 Infection and Hospitalization: A Real-World Study of 56,244 Cases in Shanghai, China.Chinese journal of integrative medicine · 2025Article
- Article
- Exploring Bioactive Phytomedicines for Advancing Pulmonary Infection Management: Insights and Future Prospects.Phytotherapy research : PTR · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lianhua-Qingwen capsule (LQC) is a commonly used Traditional Chinese Medicine (TCM) in China and has 11 herb components. The main active ingredient can target specific molecules and perform many clinic treatment roles. LQC has been authorized by National Medical Products Administration (NMPA) of China to treat severe acute respiratory syndrome (SARS) in 2002-2003, type A influenza virus HIN1 pandemic in 2009, H7N9, H3N2 and coronavirus disease-19 (COVID19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) in 2020. It is also widely used to treat common cold with wind-heat syndrome, chronic rhinosinusitis (CRS), amygdalitis and chronic obstructive pulmonary disease. This article summarizes the advanced research progress of LQC in clinical application, mechanisms and provides new clues in the clinical application of LQC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.